<DOC>
	<DOCNO>NCT00406692</DOCNO>
	<brief_summary>In study influence zonisamide administration 13 week period alcohol consumption alcoholic ( alcohol dependent ) subject examine . The dose zonisamide give subject slowly increase period several week . They receive full dose 5 week period . This pilot study subject receive zonisamide . A primary objective study determine possible size effect zonisamide administration drinking ( i.e . drink consume per day ) allow u plan large clinical trial effect zonisamide alcohol dependence .</brief_summary>
	<brief_title>The Effects Zonisamide Alcohol Dependence</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Zonisamide</mesh_term>
	<criteria>INCLUSION CRITERIA To admit study patient must meet following criterion : 1 . DSM IV TR Diagnosis Alcohol Dependence ; minimal level 14 drink per week woman 21 drink per week men 28 day consecutive period 90 day period prior screen session . 2 . Male Female 2164 year age . 3 . Able provide inform consent comprehend study procedure . 4 . Negative urine toxicological screen opioids , psychomotor stimulant , sedativehypnotics , cannabinoids . If urine tox screen positive substance may repeat within two week . 5 . Score &gt; 8 Alcohol Use Disorder Identification Test ( AUDIT ) screening . 6 . Must suitable outpatient management alcoholism . 7 . Express desire stop drinking reduce alcohol consumption possible longterm goal abstinence . 8 . Provide contact information alternate contact staff call case miss appointment . 9 . Women must postmenopausal least one year , surgically sterile , use effective method birth control ( e.g . contraceptive injection , intrauterine device , spermicide barrier , contraceptive patch , contraceptive ring , male partner sterilization , oral contraceptive ) completely abstinent ( agree use one mention method contraception sexual activity ever initiate ) . 10 . Must able take oral medication , adhere regimen willing return follow visit . 11 . Must breath alcohol concentration 0.01 % informed consent provide consent form sign . 12 . Must reside address least 3 month . EXCLUSION CRITERIA Patients meeting follow criterion exclude study : 1 . Dependent extensive abuse drug substance ethanol , nicotine , caffeine . 2 . DSM IVTR diagnosis current Axis I diagnosis alcohol dependence , nicotine dependence , caffeine dependence opinion study physician might require intervention either pharmacological nonpharmacological therapy interfere course study . 3 . Receiving inpatient outpatient treatment alcohol dependence ( exception AA selfhelp group ) within 4 week prior enrollment study . 4 . Subjects score 10 great CIWAAr ( withdrawal scale ) first second visit . 5 . Currently treat acamprosate , disulfiram naltrexone . 6 . Currently treat follow medication : ) Antipsychotic agent include clozapine , risperidone , quetiapine , haloperidol b ) Antimanic anticonvulsant agent include lithium carbonate , phenytoin , phenobarbital , carbamazepine , topiramate , valproic acid , divalproex , tiagabine c ) Sedativehypnotic antianxiety agentsincluding triazolam , temazepam , zolpidem , zalepron , buspirone , alprazolam , diazepam , clonazepam , oxazepam , lorazepam ) chronic opioid treatment include methadone , buprenorphine , oxycodone , morphine e ) Psychomotor stimulant amphetamine derivative , methylphenidate 7 . Subjects legally mandate participate alcohol treatment program 8 . Use medication know inhibit induce cytochrome P450 3A4 enzyme include macrolide antibiotic , fluoxetine , carbamazepine . 9 . Subjects attempt suicide suicidal ideation within 30 day first visit assess use response SCID Hamilton Depression scale . 10 . Subjects renal disease ( include severe infection cancer ) , impaired renal clearance ( CrCl le 50 ml/min ) , history kidney stone . 11 . Subjects AST ALT &gt; 3 time upper limit normal range screening . 12 . History significant neurological disorder , include history seizure , stroke , dementia , multiple sclerosis , Parkinson 's disease , brain tumor , encephalitis . 13 . Subjects pregnant ( assessed serum HCG ) lactating . 14 . Subjects know clinically significant medical condition . These may include : symptomatic CAD PVD , malignancy history malignancy last 5 year , significant pulmonary disease endocrinological disorder . 15 . Subjects prior hypersensitivity zonisamide related compound , include sulfonamide ( e.g . sulfisoxazole ) carbonic anhydrase inhibitor ( e.g . acetazolamide ) , sulfonylurea ( e.g . chlorpropamide ) , sulfamates ( e.g . topiramate ) , thiazide ( e.g . hydrochlorothiazide ) , loop diuretic ( e.g . furosemide ) except ethacrycrynic acid . 16 . Subjects opinion study physician enrol base precaution , warning , contraindication state package insert zonisamide . 17 . Impending incarceration . 18 . Score 25 less Folstein MiniMental examination . 19 . History anticonvulsantinduced rash .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Zonisamide</keyword>
	<keyword>Alcoholism</keyword>
	<keyword>Alcohol</keyword>
</DOC>